Tesamorelin dosage and evidence

What is Tesamorelin?

How does Tesamorelin work?

It switches on GHRH receptors on the pituitary gland. That makes the gland release growth hormone in natural bursts, and leaves the brain's normal checks on it in place.

What have studies in people found about Tesamorelin?

Tesamorelin is one of the few drugs that boost growth hormone to go all the way through the large trials needed for approval. Almost all that testing was in one group: people with HIV, on HIV medicine, who had built up deep belly fat. Two large final-stage trials in 806 patients led to its approval. Smaller university trials since then looked at liver fat and at thinking and memory. One of the memory trials found no benefit.

• Both approval trials together: 806 patients with HIV. Deep belly fat shrank by 24 square centimetres on a scan at 26 weeks, while it grew by 2 on the dummy shot. That works out to 15.4% less deep belly fat from the drug. Fat just under the skin did not change.
• First approval trial: 412 patients with HIV and belly fat took 2 mg a day for 26 weeks. Deep belly fat fell 15.2% on the drug and rose 5.0% on the dummy shot. Blood fats called triglycerides also fell.
• The follow-on stretch: 273 people on tesamorelin and 137 on the dummy shot were reassigned at week 26. Deep belly fat stayed down about 18% over 52 weeks, and triglycerides stayed 51 mg/dL lower. Blood sugar did not change in any way that mattered. When people stopped, the belly fat came back.
• Thinking in older adults: 152 adults aged 55 to 87, 66 of them with mild memory problems, took 1 mg a day for 20 weeks. Thinking improved a little, mostly in planning and focus skills. The growth hormone marker IGF-1 rose 117% but stayed in the normal range.
• Thinking in people with HIV: 73 people got tesamorelin or their usual care for 6 months. Everyone knew who got the drug, and there was no dummy shot. Thinking test scores came out the same in both groups. Waists shrank 2.7 cm more on tesamorelin. The authors say the trial was too small to be sure.
• Fatty liver in HIV: 61 people were treated for 12 months. Liver fat fell 4.1 points more than on the dummy shot, about 37% less. 35% on the drug got their liver fat under 5%, against 4% on the dummy. Blood sugar and three-month average blood sugar did not differ at 12 months.
• Belly fat and liver fat: 50 people took part and 48 were treated for 6 months. Deep belly fat fell 42 square centimetres more than on the dummy shot, and liver fat fell about 2.9 points more. Fasting blood sugar rose 7 mg/dL more than on the dummy at 2 weeks. By 6 months that gap was too small to be sure of.
• Newer HIV medicine: 38 people in the fatty liver trial were on a newer type of HIV drug that tends to add weight, and 31 finished 12 months. Their deep belly fat fell 25 square centimetres while it rose 14 on the dummy shot. Liver fat fell 4.2% against 0.5%. Blood sugar control did not get worse.

What this does not tell you: Every belly fat result here comes from people with HIV on HIV medicine. Their bodies store fat in an unusual pattern. None of it shows what tesamorelin does to belly fat in anyone else. The effect lasts only as long as the drug: in the 52-week study the fat came back after people stopped. The longest any trial ran was 12 months. Blood sugar rises early on, which matters because many people who take it already have blood sugar problems. On thinking and memory there is one good 20-week trial in 152 older adults. There is also one 6-month trial in 73 people with HIV that found nothing, where everyone knew who got the drug. That is not enough to call either way. No trial has tested whether it prevents dementia.

What do people who took Tesamorelin report?

This is what real people say happened to them, good and bad. Nobody measured it. A report cannot tell a real effect from the lift people get just from expecting it to work, from a diet or training change made at the same time, or from what was really in the vial. We still put it near the top. It is the next best thing to a study in people: what happens when real people use it, including what goes wrong.

• The most consistent thing people report, and the one that matches the trials most closely, is that this moves the deep belly fat around the organs. It does not move the fat under the skin or total weight. Experienced posters state that plainly and correct newcomers who expect weight loss from it, several of them pointing out that the trials themselves report no loss of the fat under the skin.
• Described use is around 2 mg daily for a long run, with figures of 90 to 180 days mentioned, and cost is raised repeatedly as the main obstacle. It is commonly named as one of the more expensive things in this category.
• Disappointment is a common report. People describe completing a cycle and being unimpressed, and moving to a GLP-1 drug afterwards for the outcome they originally wanted.
• Direct scepticism about the online protocol culture around this compound is itself a recurring theme, with users arguing that the five days on two days off and fixed cycle length patterns circulating on forums are not derived from anything.
• It is usually discussed alongside peptides that make the body release growth hormone, rather than alone, which makes almost every self-report about it a report about a combination.
• Some users describe it as worth using specifically for stubborn abdominal fat that has not responded to a calorie deficit, and frame that as a narrow use rather than a general one.

Sources: Public discussion in r/Peptides, r/PeptideForum, r/Peptidesource, r/trt and weight loss subreddits, read through the PullPush Reddit archive on 2026-09-13 because Reddit's own endpoints are unreachable from this environment. 90 comments reviewed. Nothing above is attributed to any specific post and no comment is reproduced.

The state of the research

The evidence, in charts

The studies we cite

• Study in people2007
  Metabolic effects of a growth hormone-releasing factor in patients with HIV

  It worked on the deep fat around the organs, in the group it was designed for. 412 people with HIV who had gained fat around the middle took a daily tesamorelin injection or a dummy injection for six months. Nobody involved knew which. Deep belly fat fell about 15% on tesamorelin. In the dummy group it rose about 5%. Blood fats improved as well. This says nothing about people without HIV, who were not studied here.

  412 patients with HIV and abdominal fat accumulation: 26 weeks of tesamorelin 2 mg daily reduced visceral adipose tissue 15.2% versus a 5.0% increase on placebo, with lower triglycerides.

  PMID 18057338 New England Journal of Medicine
• Study in people2010
  Effects of tesamorelin (TH9507) in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data

  Pooling both large trials gives the same answer. Deep fat shrinks. 806 people with HIV and extra fat around the middle took tesamorelin or a dummy injection daily for six months. On a scan, the deep fat inside the belly fell by about 24 square centimetres on tesamorelin while it crept up slightly on the dummy. That is a drop of about 15%. The fat just under the skin did not change, so the drug moves one kind of fat and leaves the other alone.

  806 patients across both phase 3 trials: VAT fell 24 cm2 at week 26 versus a 2 cm2 rise on placebo (treatment effect -15.4%), with no change in subcutaneous fat.

  PMID 20554713 Journal of Clinical Endocrinology & Metabolism
• Study in people2012
  Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial

  Thinking scores edged up, and this was one modest trial. 152 adults aged 55 to 87 took tesamorelin or a dummy injection daily for about five months. Sixty six of them already had mild memory problems. The drug group did a little better at tests of planning and mental flexibility, by enough to separate from chance. IGF-1 more than doubled but stayed inside the normal range. No other team has repeated this, it ran only five months, and it did not test whether anyone's memory loss progressed.

  152 adults aged 55 to 87 (66 with MCI): 20 weeks of tesamorelin 1 mg daily had a favorable effect on cognition (P=.03), mainly executive function, and raised IGF-1 117% within the physiological range.

  PMID 22869065 Archives of Neurology
• Study in people2019
  Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial

  It worked on liver fat, in a small trial. 61 people with HIV and a fatty liver were split evenly and given a daily injection of tesamorelin or a dummy version for a year. Nobody involved knew which. Liver fat came down by about a third more on tesamorelin than on the dummy. By the end 35% of the tesamorelin group had liver fat back under the normal threshold, against 4% on the dummy. With 61 people this is a first answer, not a settled one.

  61 people with HIV and NAFLD (NCT02196831) randomized 30 to 30 to 12 months of tesamorelin 2 mg daily or placebo, with hepatic fat fraction as the primary endpoint. Hepatic fat fraction fell further on tesamorelin, absolute effect minus 4.1 percent (95% CI minus 7.6 to minus 0.7, p = 0.018), a minus 37 percent relative reduction (95% CI minus 67 to minus 7, p = 0.016). At 12 months 35 percent on tesamorelin and 4 percent on placebo had a hepatic fat fraction under 5 percent (p = 0.0069). Fasting glucose and glycated haemoglobin did not differ between groups. Injection site complaints were more common on tesamorelin, none judged serious.

  PMID 31611038 The Lancet HIV
• Study in people2008
  Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation

  The fat stayed off while people kept injecting, and came back when they stopped. 273 people on tesamorelin and 137 on the dummy shot were reassigned at the halfway mark and followed to a year. Deep belly fat around the organs stayed about 18% down over the full year, and blood triglycerides stayed 51 mg/dL lower. Once the injections stopped, the deep fat came back. This is a drug people have to keep taking to keep the result.

  26-week extension in which 273 tesamorelin and 137 placebo patients were re-randomized: visceral fat reduction sustained at -18% over 52 weeks and triglycerides at -51 mg/dL, with reaccumulation of visceral fat after discontinuation.

  PMID 18690162 AIDS
• Study in people2014
  Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial

  Tesamorelin shrank both deep belly fat and liver fat, in a small trial. 50 people with HIV and belly fat were split by chance, and 48 were treated for six months. Deep fat around the organs fell 42 cm2 more than on the dummy shot, and liver fat fell about 3 percentage points more. Fasting blood sugar rose 7 mg/dL more than the dummy in the first two weeks. By six months that blood sugar difference had gone.

  50 randomized, 48 treated over 6 months: visceral fat treatment effect -42 cm2 (95% CI -71 to -14) and net liver fat -2.9% lipid-to-water. Fasting glucose rose 7 mg/dL more than placebo at 2 weeks.

  PMID 25038357 JAMA
• Study in people2024
  Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors

  The drug still worked in people taking the newer HIV medicines that tend to add weight. 38 of the 61 people in this trial were on integrase inhibitors, and 31 finished the year. Their deep belly fat fell about 25 cm2 while it rose about 14 cm2 on the dummy shot, and liver fat fell 4.2% against 0.5%. Blood sugar control did not get worse. This is a slice of a small trial, not a trial of its own.

  38 participants on integrase-inhibitor regimens within a 61-person randomized trial, 31 completing 12 months: median visceral fat -25 cm2 versus +14 cm2 and hepatic fat -4.2% versus -0.5%, without worsening glycemic control.

  PMID 38905488 AIDS
• Study in people2025
  Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity

  Tesamorelin did not improve thinking or memory, and this trial was too small to settle the question. 73 people with HIV and belly fat were assigned to the drug or to usual care for six months. Everybody knew who was getting it. Scores on the thinking tests came out the same in both groups. Waists did shrink 2.7 cm more on the drug. The authors say the trial had too few people and no dummy group, so a real effect could have been missed.

  73 participants randomized 3:2, open label, 6 months: the between-group difference in neurocognitive performance was not significant (P=.673) despite a greater fall in waist circumference. The authors report the trial was underpowered and had no placebo arm.

  PMID 39813152 Journal of Infectious Diseases
• Review of studies2010
  Egrifta (tesamorelin) approval package, NDA 022505

  The FDA's approval papers for tesamorelin. They approve it to cut extra belly fat in people with HIV who have lipodystrophy.

  FDA approval documentation for tesamorelin to reduce excess abdominal fat in HIV-infected patients with lipodystrophy.

  Source U.S. Food and Drug Administration